EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV

Chunchun Liu iD, Yulei Ren iD, Xuan Luo, Peiyun Zhou, Xiangjuan Du, Qianmin Wang, Xue Han, Yanhui Xu, Ping Wang, Dan Zhao iD, Huirong Yang

PLOS One · 2026

DOI: 10.1371/journal.pone.0338127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Chunchun Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laborator…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Signal Transduction, Antibodies, Monoclonal. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2), a ligand-independent tyrosine kinase receptor belonging to the EGFR family, serves as a key oncogenic driver in breast, gastric, and several other solid tumors. Although anti-HER2 therapies have substantially improved survival outcomes—particularly in breast and gastric cancers—treatment resistance and cancer recurrence remain major clinical challenges. Thus, developing novel antibodies exhibiting complementary effects to the current anti-HER2 therapies could provide additional therapeutic benefits. Here, we describe two novel HER2-targeting monoclonal antibodies, m66 (murine-derived) and r40 (rabbit-derived), which inhibit breast cancer cell proliferation in vitro . Of the two, antibody r40 exhibits stronger suppression of the PI3K/AKT and MAPK signaling pathways compared to m66. Moreover, the addition of r40 to the combination of trastuzumab and pertuzumab leads to a significantly enhanced inhibitory effect. We also determined the cryo-EM structures of the HER2-m66-trastuzumab ternary complex and the HER2-r40-trastuzumab-pertuzumab tetrameric complex, at overall resolutions of 3.2 Å and 3.1 Å, respectively. Structural analyses reveal that m66 recognizes an epitope overlapping with that of pertuzumab, whereas r40 binds within the HER2 ECD III/IV—a region distinct from the binding sites of both trastuzumab and pertuzumab. These findings identify r40 as a promising therapeutic candidate for use in combination with trastuzumab and pertuzumab in the treatment of HER2-positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsSignal TransductionAntibodies, MonoclonalHumansFemaleCell ProliferationTrastuzumabAntibodies, Monoclonal, HumanizedCell Line, TumorAnimals

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabAntibodies, Monoclonal, HumanizedERBB2 protein, humanAntibodies, Monoclonalpertuzumab

Autor:innen und Institutionen

  • Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University…
  • Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • The International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Shanghai, China.
  • Department of Systems Biology for Medicine, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.
  • Molinsights Biotechnologies, Guangdong Medical Valley Life Science Park, Guangzhou, China.

ORCID-Profile: Chunchun Liu, Yulei Ren, Dan Zhao

Förderung

  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Liu, C., Ren, Y., Luo, X., Zhou, P., Du, X., Wang, Q., Han, X., Xu, Y., Wang, P., Zhao, D., & Yang, H. (2026). Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV. PLOS One. https://doi.org/10.1371/journal.pone.0338127

Vancouver

Liu C, Ren Y, Luo X, Zhou P, Du X, Wang Q, et al. Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV. PLOS One. 2026. doi:10.1371/journal.pone.0338127

BibTeX
@article{Liu2026,
  author = {Liu, Chunchun and Ren, Yulei and Luo, Xuan and Zhou, Peiyun and Du, Xiangjuan and Wang, Qianmin and Han, Xue and Xu, Yanhui and Wang, Ping and Zhao, Dan and Yang, Huirong},
  title = {Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0338127}
}
Kostenlos starten →